Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection
- PMID: 15364110
- DOI: 10.1016/j.femsim.2004.05.008
Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection
Erratum in
- FEMS Immunol Med Microbiol. 2005 Jan 1;43(1):103
Abstract
In this report, we investigated the effect of ODN containing immunostimulatory CG motifs as adjuvant with soluble antigen (SA) from Leishmania donovani. BALB/c mice were vaccinated with the soluble antigen with or without CpG-ODN as adjuvant and then challenged with L. donovani metacyclic promastigotes. CpG-ODN alone resulted in partial protection against challenge with L. donovani. Immunization of mice with SA and CpG-ODN showed enhanced reduction in parasite load ( approximately 60%) when compared to SA ( approximately 40%) immunized mice. Immunization with SA by itself resulted in a mixed Th1/Th2 response whereas co-administration of SA with CpG-ODN resulted in a strong Th1 promoting isotype as they together promoted production of immunoglobulin G2a. Leishmania-specific Th1 cytokine response was induced by co-administering CpG-ODN and SA as they together promoted production of IFN-gamma and IL-12. In the present study, we demonstrate that immunostimulatory phosphorothioate-modified ODN are promising immune enhancers for vaccination against visceral leishmaniaisis.
Similar articles
-
Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.Vaccine. 2004 Aug 13;22(23-24):3053-60. doi: 10.1016/j.vaccine.2004.02.007. Vaccine. 2004. PMID: 15297055
-
Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.Infect Immun. 2005 Sep;73(9):5842-52. doi: 10.1128/IAI.73.9.5842-5852.2005. Infect Immun. 2005. PMID: 16113303 Free PMC article.
-
A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.Vaccine. 2004 Mar 12;22(9-10):1162-71. doi: 10.1016/j.vaccine.2003.09.030. Vaccine. 2004. PMID: 15003644
-
The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.J Leukoc Biol. 2000 Oct;68(4):455-63. J Leukoc Biol. 2000. PMID: 11037965 Review.
-
Progress in vaccine research and possible effector mechanisms in visceral leishmaniasis.Curr Mol Med. 2004 Sep;4(6):697-709. doi: 10.2174/1566524043360212. Curr Mol Med. 2004. PMID: 15357218 Review.
Cited by
-
Development of Vaccines against Visceral Leishmaniasis.J Trop Med. 2012;2012:892817. doi: 10.1155/2012/892817. Epub 2011 Sep 5. J Trop Med. 2012. PMID: 21912561 Free PMC article.
-
Toll-like Receptor-9 (TLR-9) Signaling Is Crucial for Inducing Protective Immunity following Immunization with Genetically Modified Live Attenuated Leishmania Parasites.Pathogens. 2023 Mar 29;12(4):534. doi: 10.3390/pathogens12040534. Pathogens. 2023. PMID: 37111420 Free PMC article.
-
Identification of Leishmania donovani antigens stimulating cellular immune responses in exposed immune individuals.Clin Exp Immunol. 2006 Feb;143(2):380-8. doi: 10.1111/j.1365-2249.2005.03000.x. Clin Exp Immunol. 2006. PMID: 16412064 Free PMC article.
-
Anti-Leishmanial Vaccines: Assumptions, Approaches, and Annulments.Vaccines (Basel). 2019 Oct 18;7(4):156. doi: 10.3390/vaccines7040156. Vaccines (Basel). 2019. PMID: 31635276 Free PMC article. Review.
-
Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN.Parasitol Res. 2011 May;108(5):1265-73. doi: 10.1007/s00436-010-2176-4. Epub 2010 Dec 2. Parasitol Res. 2011. PMID: 21125294
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources